Neurological Biomarkers Market

Neurological Biomarkers Market: Product Diversification Remains Key Strategy for Manufacturers: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2025)

Ask The Analyst Customization Available Request Methodology

Genomics emerges as the trending biomarker type, and is expected to witness impressive growth

Neurology disorders are affecting major percentage of the global population and it is considered a major cause of disability around the globe. The prevalence of neurological disorders is growing at a very high pace, in which biomarkers are expected play a vital role in better understanding of the disease and development of personalized medicine specific to the patient. There are different types of biomarkers in the market, such as Genomics Biomarker, Proteomics Biomarker, Metabolomics Biomarkers, Imaging Biomarkers, Others. Among these, geonomics biomarker is expected to hold a higher market value reach over US$ 2,700 Mn by the end of 2025.

With the advancements taking place in the healthcare industry and expansion of neurological biomarkers market, new trends are being introduced in the market. A latest trend introduces genomics to the biomarkers market. The process is considered to be an efficient process of examining a disease at the genetic level. It can play major role in the drug development and personalized medicine too. Imaging biomarkers has also come up as one attractive biomarker type, which is expected to witness growth at a high rate in the years coming ahead. Metabolomics biomarkers is also one of these attractive category in the market which is expected to be a lucrative segment in the coming years.

Neurological-Biomakers-Market.jpg

Neurological biomarkers market stands strong in terms of business, as the market demands personalized medicines

Early diagnosis of neurological diseases plays a crucial role in successful management of the disease. Neurological system has limited accessibility and thus, makes diagnosis of the disease a difficult process. Moreover, presently available diagnostic procedures lack sensitivity and specificity for evaluation of disease progression and prognosis. Neurological disorders are diagnosed with cognitive testing, clinical history, structural MRI and neurological examination. However, there are few circumstances wherein identification of specific biomarker is required to understand the diagnosis and treatment of the disease. Biomarker is considered as an indicator in evaluation and measurement of a pathological and physiological process or indicator for pharmacological response to a treatment. Biomarkers are common reference point for diagnosis of disease and play a major role in the development of personalized medicine. There has been significant progress in understanding of onset and development of neurological diseases at the epigenomic and genomic levels. It leads to rapid development of biomarkers in diagnosis of disease with main emphasis in personalized medicine. The growth is expected to take place rapidly, with the requirements of personalized medicines in the coming years.

The market is expected to be stay active also with the increase in research initiatives taking place.  There is a huge demand for identifying and validating biomarkers from a large number of population and conducting the research process with the help of this method. It is anticipated to be major factor marking the growth of neurological biomarkers market.

Heterogeneity of Disease turns out to be a stout hindrance in the growth of neurological biomarkers market

In case of heterogeneity, the same disease phenotype is produced with multiple interrelated processes and it increases the difficulty of discovery of biomarkers in degenerative diseases. Such cases can be misleading and increases the complications of the detection and analysis process. It leads to confusion between abnormal and normal health conditions. The clinical symptoms of one disease may be identified by number of heterogeneous Omics variations. Such cases can tone down the expectations of people from neurological biomarkers process and also hamper the growth of its market globally.

Global Healthcare Services Sector Outlook

There is growing consensus among healthcare providers that the current fee-for-services payment mechanism needs an overhaul. While fee-for-services is the pervasive method of billing patients, alternative processes, such as capitation and pay-for-performance are also being considered. We anticipate fee-for-services to be supplemented by capitation and pay-for-performance in the future. In addition to charging patients for screening and doctor visits, pay-for-performance can lead to higher quality of care, as other essential tasks will also be billed. It may lead to an increase in healthcare costs, with the promise that quality of care will go up.

The healthcare system is in a phase where access to capital is constantly diminishing. Big spends are rare and there is increasing uncertainty among borrowers about their ability to repay loans and funding. Healthcare institutions are either postponing large capital-intensive projects or allocating resources to specialty areas that offer a high ROI. Cash-constraints will result into an increase in mergers and acquisitions and lead to fundraising from healthcare providers. However, as only a select few will qualify for an acquisition or funding, the effects of cash-crunch will be palpable in this sector.

Healthcare providers and insurers are aware of the rapidly increasingly population and their growing healthcare needs. The impact is more palpable in the U.S. and Japan – important markets in terms of their standing in the global healthcare market. Providers and insurers are strategizing to tap into the available opportunities in this demographic. Baby boomers around the globe are actively taking charge of their health. Smartphone remains the primary source of information-seeking for this segment. With over 70,000 websites and hundreds of apps disseminating information, providers and insurers will focus on strengthening their digital presence to effectively target this demographic.

Research Methodology

FMI utilizes robust methodology and approach to arrive at market size and related projections. The research methodology for this report is based on 3 dimensional model. We conduct about 45-60 min duration detailed interviews with product manufacturers; apart from this we also collect market feedback from industry experts. To validate this data, we interact with senior panel members having more than 10 years of experience in relevant field. The panel members help in validating the findings and fill the gaps if any.  In addition, we leverage on our existing pool of information, paid database and other valid information sources available in public domain. Usually industry interactions extend to more than 50+ interviews from market participants across the value chain.

Data Collection

FMI collects data from secondary sources including company annual reports, association publications, industry presentations, white papers, and company press releases apart from these we leverage over paid database subscriptions and industry magazines to collect market information and developments in exhaustive manner. After being done with desk research, detailed questionnaire and discussion guide is formulated to initiate primary research with key industry personnel; the discussion aims at collecting key insights, growth perspectives, prevalent market trends and quantitative insights including market size and competition developments. Both of these research approaches help us in arriving at base year numbers and market hypothesis.

Data Validation

In this phase, FMI validates the data using macro and micro economic factors. For instance, growth in electricity consumption, industry value added, other industry factors, economic performance, growth of top players and sector performance is closely studied to arrive at precise estimates and refine anomalies if any.

Data Analysis and Projection

Data analysis and projections were made based on proprietary research frameworks and statistical analysis, which was further validated from industry participants. These frameworks include Y-o-Y growth projections, macro-economic factor performance, market attractiveness analysis, key financial ratios, and others.

For public companies we capture the data from company website, annual reports, and investor presentations, paid databases. While for privately held companies, we try to gather information from the paid databases (like Factiva) and based on the information we gather from databases we estimate revenue for the companies. In addition, the team tries to establish primary contact with the companies in order to validate the assumptions or to gather quality inputs.

Standard Report Structure

  • Executive Summary

  • Market Definition

  • Macro-economic analysis

  • Parent Market Analysis

  • Market Overview

  • Forecast Factors

  • Segmental Analysis and Forecast

  • Regional Analysis

  • Competition Analysis

Target Audience

  • Physicians

  • Surgeons

  • Pathology In charge

  • Procurement Manager

  • Laboratory Technicians

  • Hospital Accountants

  • Independent Consultants

  • Government Authorities

Market Taxonomy

By Type

  • Genomics Biomarker

  • Proteomics Biomarker

  • Metabolomics Biomarkers

  • Imaging Biomarkers

  • Others

By Application

  • Alzheimer's Disease

  • Parkinson's Disease

  • Huntington's Disease

  • Schizophrenia

  • Depression

  • Multiple Sclerosis

  • Spinal Muscular Atrophy

By End User

  • Research Organizations, Pharma & Biotech Companies

  • Clinical Diagnostics

By region

  • North America

  • Latin America

  • Europe

  • Asia-Pacific

  • Middle East & Africa

Neurological Biomarkers Market Reports - Table of Contents

1. Executive Summary

A gist of the report, highlighting the key takeaways

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

A definition of Neurological Biomarkers and related market taxonomy

2.1. Market Definition

2.2. Market Taxonomy

2.3. Neurological Biomarkers Market Overview

2.4. Company and Chief Analyst Credentials

3. Market View Point

Tracking the market scenario, with key inferences drawn from historical data, current trends, and future prospects

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

4. Market Background

4.1. Technology Evolution and List of Neurological Biomarkers

4.2. List of Growth Hacking Manufacturers

5. Industry Structure

5.1. Marketing and Distribution Strategies

5.2. Market Size by Tiers

6. Macroeconomic Assumptions

7. Global Economic Outlook

7.1. Gross Domestic Product by Region & Country, 2006 – 2021

7.2. Disease Outlook

8. North America Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025

Market forecast and analysis in the U.S. and Canada

8.1. Introduction

8.2. Key Regulations

8.3. Regional Market Dynamics

8.3.1. Drivers

8.3.2. Restraints

8.3.3. Trends

8.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

8.4.1. U.S.

8.4.2. Canada

8.5. Market Size (US$ Mn) Forecast By Country, 2017–2025

8.5.1. U.S.

8.5.2. Canada

8.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016

8.6.1. Genomics Biomarker

8.6.2. Proteomic Biomarker

8.6.3. Metabolomics Biomarker

8.6.4. Imaging biomarkers

8.6.5. Others

8.7. Market Size (US$ Mn) Forecast By Type, 2017–2025

8.7.1. Genomics Biomarker

8.7.2. Proteomic Biomarker

8.7.3. Metabolomics Biomarker

8.7.4. Imaging biomarkers

8.7.5. Others

8.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

8.8.1. Alzheimer’s disease

8.8.2. Parkinson’s disease

8.8.3. Huntington’s disease

8.8.4. Schizophrenia

8.8.5. Depression

8.8.6. Multiple Sclerosis

8.8.7. Spinal Muscular Atrophy (SMA)

8.9. Market Size (US$ Mn) Forecast By Application, 2017-2025

8.9.1. Alzheimer’s disease

8.9.2. Parkinson’s disease

8.9.3. Huntington’s disease

8.9.4. Schizophrenia

8.9.5. Depression

8.9.6. Multiple Sclerosis

8.9.7. Spinal Muscular Atrophy (SMA)

8.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

8.10.1. Research Institutes and Diagnostic Centers

8.10.2. Hospitals

8.11. Market Size (US$ Mn) Forecast By End User, 2017-2025

8.11.1. Research Institutes and Diagnostic Centers

8.11.2. Hospitals

8.12. Market Attractiveness Analysis

8.12.1. By Country

8.12.2. By Type

8.12.3. By Application

8.12.4. By End User

8.13. Key Representative Market Participants

8.14. Key Participants Market Presence (Intensity Map)

9. Latin America Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025

Market forecast and analysis in Brazil, Mexico, Argentina and Rest of Latin America

9.1. Introduction

9.2. Key Regulations

9.3. Regional Market Dynamics

9.3.1. Drivers

9.3.2. Restraints

9.3.3. Trends

9.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

9.4.1. Brazil

9.4.2. Mexico

9.4.3. Argentina

9.4.4. Rest of Latin America

9.5. Market Size (US$ Mn) Forecast By Country, 2017–2025

9.5.1. Brazil

9.5.2. Mexico

9.5.3. Argentina

9.5.4. Rest of Latin America

9.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016

9.6.1. Genomics Biomarker

9.6.2. Proteomic Biomarker

9.6.3. Metabolomics Biomarker

9.6.4. Imaging biomarkers

9.6.5. Others

9.7. Market Size (US$ Mn) Forecast By Type, 2017–2025

9.7.1. Genomics Biomarker

9.7.2. Proteomic Biomarker

9.7.3. Metabolomics Biomarker

9.7.4. Imaging biomarkers

9.7.5. Others

9.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

9.8.1. Alzheimer’s disease

9.8.2. Parkinson’s disease

9.8.3. Huntington’s disease

9.8.4. Schizophrenia

9.8.5. Depression

9.8.6. Multiple Sclerosis

9.8.7. Spinal Muscular Atrophy (SMA)

9.9. Market Size (US$ Mn) Forecast By Application, 2017-2025

9.9.1. Alzheimer’s disease

9.9.2. Parkinson’s disease

9.9.3. Huntington’s disease

9.9.4. Schizophrenia

9.9.5. Depression

9.9.6. Multiple Sclerosis

9.9.7. Spinal Muscular Atrophy (SMA)

9.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

9.10.1. Research Institutes and Diagnostic Centers

9.10.2. Hospitals

9.11. Market Size (US$ Mn) Forecast By End User, 2017-2025

9.11.1. Research Institutes and Diagnostic Centers

9.11.2. Hospitals

9.12. Market Attractiveness Analysis

9.12.1. By Country

9.12.2. By Type

9.12.3. By Application

9.12.4. By End User

9.13. Key Representative Market Participants

9.14. Key Participants Market Presence (Intensity Map)

10. Europe Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025

Market forecast and analysis in Germany, France, Italy, Spain, U.K., Russia, and rest of Europe

10.1. Introduction

10.2. Key Regulations

10.3. Regional Market Dynamics

10.3.1. Drivers

10.3.2. Restraints

10.3.3. Trends

10.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

10.4.1. Germany

10.4.2. France

10.4.3. U.K.

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Rest of Europe

10.5. Market Size (US$ Mn) Forecast By Country, 2017–2025

10.5.1. Germany

10.5.2. France

10.5.3. U.K.

10.5.4. Spain

10.5.5. Italy

10.5.6. Russia

10.5.7. Rest of Europe

10.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016

10.6.1. Genomics Biomarker

10.6.2. Proteomic Biomarker

10.6.3. Metabolomics Biomarker

10.6.4. Imaging biomarkers

10.6.5. Others

10.7. Market Size (US$ Mn) Forecast By Type, 2017–2025

10.7.1. Genomics Biomarker

10.7.2. Proteomic Biomarker

10.7.3. Metabolomics Biomarker

10.7.4. Imaging biomarkers

10.7.5. Others

10.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

10.8.1. Alzheimer’s disease

10.8.2. Parkinson’s disease

10.8.3. Huntington’s disease

10.8.4. Schizophrenia

10.8.5. Depression

10.8.6. Multiple Sclerosis

10.8.7. Spinal Muscular Atrophy (SMA)

10.9. Market Size (US$ Mn) Forecast By Application, 2017-2025

10.9.1. Alzheimer’s disease

10.9.2. Parkinson’s disease

10.9.3. Huntington’s disease

10.9.4. Schizophrenia

10.9.5. Depression

10.9.6. Multiple Sclerosis

10.9.7. Spinal Muscular Atrophy (SMA)

10.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

10.10.1. Research Institutes and Diagnostic Centers

10.10.2. Hospitals

10.11. Market Size (US$ Mn) Forecast By End User, 2017-2025

10.11.1. Research Institutes and Diagnostic Centers

10.11.2. Hospitals

10.12. Market Attractiveness Analysis

10.12.1. By Country

10.12.2. By Type

10.12.3. By Application

10.12.4. By End User

10.13. Key Representative Market Participants

10.14. Key Participants Market Presence (Intensity Map)

11. Asia Pacific Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025

Market forecast and analysis in China, India, Japan, ASEAN, Australia & New Zealand, and Rest of Asia Pacific

11.1. Introduction

11.2. Key Regulations

11.3. Regional Market Dynamics

11.3.1. Drivers

11.3.2. Restraints

11.3.3. Trends

11.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

11.4.1. China

11.4.2. India

11.4.3. Japan

11.4.4. Australia and New Zealand

11.4.5. ASEAN

11.4.6. Rest of Asia Pacific

11.5. Market Size (US$ Mn) Forecast By Country, 2017–2025

11.5.1. China

11.5.2. India

11.5.3. Japan

11.5.4. Australia and New Zealand

11.5.5. ASEAN

11.5.6. Rest of Asia Pacific

11.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016

11.6.1. Genomics Biomarker

11.6.2. Proteomic Biomarker

11.6.3. Metabolomics Biomarker

11.6.4. Imaging biomarkers

11.6.5. Others

11.7. Market Size (US$ Mn) Forecast By Type, 2017–2025

11.7.1. Genomics Biomarker

11.7.2. Proteomic Biomarker

11.7.3. Metabolomics Biomarker

11.7.4. Imaging biomarkers

11.7.5. Others

11.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

11.8.1. Alzheimer’s disease

11.8.2. Parkinson’s disease

11.8.3. Huntington’s disease

11.8.4. Schizophrenia

11.8.5. Depression

11.8.6. Multiple Sclerosis

11.8.7. Spinal Muscular Atrophy (SMA)

11.9. Market Size (US$ Mn) Forecast By Application, 2017-2025

11.9.1. Alzheimer’s disease

11.9.2. Parkinson’s disease

11.9.3. Huntington’s disease

11.9.4. Schizophrenia

11.9.5. Depression

11.9.6. Multiple Sclerosis

11.9.7. Spinal Muscular Atrophy (SMA)

11.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

11.10.1. Research Institutes and Diagnostic Centers

11.10.2. Hospitals

11.11. Market Size (US$ Mn) Forecast By End User, 2017-2025

11.11.1. Research Institutes and Diagnostic Centers

11.11.2. Hospitals

11.12. Market Attractiveness Analysis

11.12.1. By Country

11.12.2. By Type

11.12.3. By Application

11.12.4. By End User

11.13. Key Representative Market Participants

11.14. Key Participants Market Presence (Intensity Map)

12. MEA Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025

Market forecast and analysis in GCC, South Africa, and Rest of MEA

12.1. Introduction

12.2. Key Regulations

12.3. Regional Market Dynamics

12.3.1. Drivers

12.3.2. Restraints

12.3.3. Trends

12.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

12.4.1. GCC Countries

12.4.2. South Africa

12.4.3. Rest of MEA

12.5. Market Size (US$ Mn) Forecast By Country, , 2017–2025

12.5.1. GCC Countries

12.5.2. South Africa

12.5.3. Rest of MEA

12.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016

12.6.1. Genomics Biomarker

12.6.2. Proteomic Biomarker

12.6.3. Metabolomics Biomarker

12.6.4. Imaging biomarkers

12.6.5. Others

12.7. Market Size (US$ Mn) Forecast By Type, 2017–2025

12.7.1. Genomics Biomarker

12.7.2. Proteomic Biomarker

12.7.3. Metabolomics Biomarker

12.7.4. Imaging biomarkers

12.7.5. Others

12.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

12.8.1. Alzheimer’s disease

12.8.2. Parkinson’s disease

12.8.3. Huntington’s disease

12.8.4. Schizophrenia

12.8.5. Depression

12.8.6. Multiple Sclerosis

12.8.7. Spinal Muscular Atrophy (SMA)

12.9. Market Size (US$ Mn) Forecast By Application, 2017-2025

12.9.1. Alzheimer’s disease

12.9.2. Parkinson’s disease

12.9.3. Huntington’s disease

12.9.4. Schizophrenia

12.9.5. Depression

12.9.6. Multiple Sclerosis

12.9.7. Spinal Muscular Atrophy (SMA)

12.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

12.10.1. Research Institutes and Diagnostic Centers

12.10.2. Hospitals

12.11. Market Size (US$ Mn) Forecast By End User, 2017-2025

12.11.1. Research Institutes and Diagnostic Centers

12.11.2. Hospitals

12.12. Market Attractiveness Analysis

12.12.1. By Country

12.12.2. By Type

12.12.3. By Application

12.12.4. By End User

12.13. Key Representative Market Participants

12.14. Key Participants Market Presence (Intensity Map)

13. Forecast Factors: Relevance and Impact

14. Forecast Assumptions

A glossary of assumption and acronyms used in the report

15. Competition Landscape

Profile of some of the key market players, with specific focus on business and strategy

15.1. Competition Intensity Mapping By Market Taxonomy

15.2. Competition Dashboard

15.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

15.3.1. Quanterix

15.3.2. Myriad RBM

15.3.3. QIAGEN

15.3.4. ADx NeuroSciences NV

15.3.5. Merck KGaA

15.3.6. Euroimmun

15.3.7. Thermo Fisher Scientific

15.3.8. BioCrypton

15.3.9. ACOBIOM

15.3.10. Banyan Biomarkers, Inc.

15.3.11. Olink Biosciences

15.3.12. BioAgilytix

16. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025, By Region

A detailed, region-wise assessment, providing projections on market growth in key regions

16.1. Introduction / Key Findings

16.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2016

16.2.1. North America

16.2.2. Latin America

16.2.3. Europe

16.2.4. Asia Pacific

16.2.5. MEA

16.3. Market Size (US$ Mn) Forecast By Region, 2017-2025

16.3.1. North America

16.3.2. Latin America

16.3.3. Europe

16.3.4. Asia Pacific

16.3.5. MEA

16.4. Market Attractiveness Analysis By Region

17. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025, By Type

Classification of neurological biomarkers into Types; highlighting historical trends, current market value, and future projections on the basis of key segments

17.1. Introduction

17.2. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016

17.2.1. Genomics Biomarker

17.2.2. Proteomic Biomarker

17.2.3. Metabolomics Biomarker

17.2.4. Imaging biomarkers

17.2.5. Others

17.3. Market Size (US$ Mn) Forecast By Type, 2017–2025

17.3.1. Genomics Biomarker

17.3.2. Proteomic Biomarker

17.3.3. Metabolomics Biomarker

17.3.4. Imaging biomarkers

17.3.5. Others

17.4. Key Trends / Developments

17.5. Market Attractiveness Analysis By Type

18. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025, By Application

Classification based on application; highlighting historical trends, current market value, and future projections on the basis of key segments

18.1. Introduction

18.2. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

18.2.1. Alzheimer’s disease

18.2.2. Parkinson’s disease

18.2.3. Huntington’s disease

18.2.4. Schizophrenia

18.2.5. Depression

18.2.6. Multiple Sclerosis

18.2.7. Spinal Muscular Atrophy (SMA)

18.3. Market Size (US$ Mn) Forecast By Application, 2017-2025

18.3.1. Alzheimer’s disease

18.3.2. Parkinson’s disease

18.3.3. Huntington’s disease

18.3.4. Schizophrenia

18.3.5. Depression

18.3.6. Multiple Sclerosis

18.3.7. Spinal Muscular Atrophy (SMA)

18.4. Key Trends / Developments

18.5. Market Attractiveness Analysis By Application

19. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025, By End User

Assessment of End Users for neurological biomarkers; highlighting historical trends, current market value, and future projections on the basis of key segments

19.1. Introduction

19.2. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

19.2.1. Research Institutes and Diagnostic Centers

19.2.2. Hospitals

19.3. Market Size (US$ Mn) Forecast By End User, 2017-2025

19.3.1. Research Institutes and Diagnostic Centers

19.3.2. Hospitals

19.4. Key Trends / Developments

19.5. Market Attractiveness Analysis By End User

20. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025

Tracking the market scenario, with key inferences drawn from historical data, current trends, and future prospects

20.1. Market Size and Y-o-Y Growth

20.2. Absolute $ Opportunity

21. Research Methodology

Neurological Biomarkers Market Reports - List of Tables

Table 01 : North America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 02 : North America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type

Table 03 : North America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application

Table 04 : North America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User

Table 05 : Latin America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 06 : Latin America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type

Table 07 : Latin America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application

Table 08 : Latin America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User

Table 09 : Europe Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 10 : Europe Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type

Table 11 : Europe Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application

Table 12 : Europe Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User

Table 13 : Asia Pacific Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 14 : Asia Pacific Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type

Table 15 : Asia Pacific Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application

Table 16 : Asia Pacific Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User

Table 17 : Middle East & Africa Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 18 : Middle East & Africa Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type

Table 19 : Middle East & Africa Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application

Table 20 : Middle East & Africa Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User

Table 21 : Global Neurological Biomarkers Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Region, 

Table 22 : Global Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type

Table 23 : Global Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application

Table 24 : Global Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User

Neurological Biomarkers Market Reports - List of Figures

Figure 01 : Global Neurological Biomarkers Market Split By Type (2017)

Figure 02 : Global Neurological Biomarkers Market Split By Application (2017)

Figure 03 : Global Neurological Biomarkers Market Split By End User (2017)

Figure 04 : Global Neurological Biomarkers Market Split By Region (2017)

Figure 05 : North America Neurological Biomarkers Market Value Share (%) By Type (2017)

Figure 06 : North America Neurological Biomarkers Market Value Share (%) By Application (2017)

Figure 07 : North America Neurological Biomarkers Market Value Share (%) By End User (2017)

Figure 08 : North America Neurological Biomarkers Market Value Share (%) By Country (2017)

Figure 09 : North America Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025

Figure 10 : North America Neurological Biomarkers Market Size Analysis, 2012–2016

Figure 11 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 12 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker

Figure 13 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker

Figure 14 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers

Figure 15 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers

Figure 16 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers

Figure 17 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers

Figure 18 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers

Figure 19 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers

Figure 20 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Others

Figure 21 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others

Figure 22 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease

Figure 23 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease

Figure 24 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease

Figure 25 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease

Figure 26 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease

Figure 27 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease

Figure 28 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia

Figure 29 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia 

Figure 30 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression

Figure 31 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression

Figure 32 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis

Figure 33 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis

Figure 34 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy

Figure 35 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy

Figure 36 : North America Neurological Biomarkers Market Attractiveness Analysis, By Country

Figure 37 : North America Neurological Biomarkers Market Attractiveness Analysis, By Type

Figure 38 : North America Neurological Biomarkers Market Attractiveness Analysis, By Application

Figure 39 : North America Neurological Biomarkers Market Attractiveness Analysis, By End User

Figure 40 : Latin America Neurological Biomarkers Market Value Share (%) By Type (2017)

Figure 41 : Latin America Neurological Biomarkers Market Value Share (%) By Application (2017)

Figure 42 : Latin America Neurological Biomarkers Market Value Share (%) By End User (2017)

Figure 43 : Latin America Neurological Biomarkers Market Value Share (%) By Country (2017)

Figure 44 : Latin America Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025

Figure 45 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016

Figure 46 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 47 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker

Figure 48 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker

Figure 49 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers

Figure 50 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers

Figure 51 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers

Figure 52 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers

Figure 53 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers

Figure 54 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers

Figure 55 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Others

Figure 56 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others

Figure 57 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease

Figure 58 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease

Figure 59 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease

Figure 60 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease

Figure 61 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease

Figure 62 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease

Figure 63 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia

Figure 64 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia 

Figure 65 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression

Figure 66 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression

Figure 67 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis

Figure 68 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis

Figure 69 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy

Figure 70 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy

Figure 71 : Latin America Neurological Biomarkers Market Attractiveness Analysis, By Country

Figure 72 : Latin America Neurological Biomarkers Market Attractiveness Analysis, By Type

Figure 73 : Latin America Neurological Biomarkers Market Attractiveness Analysis, By Application

Figure 74 : Latin America Neurological Biomarkers Market Attractiveness Analysis, By End User

Figure 75 : Europe Neurological Biomarkers Market Value Share (%) By Type (2017)

Figure 76 : Europe Neurological Biomarkers Market Value Share (%) By Application (2017)

Figure 77 : Europe Neurological Biomarkers Market Value Share (%) By End User (2017)

Figure 78 : Europe Neurological Biomarkers Market Value Share (%) By Country (2017)

Figure 79 : Europe Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025

Figure 80 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016

Figure 81 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 82 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker

Figure 83 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker

Figure 84 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers

Figure 85 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers

Figure 86 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers

Figure 87 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers

Figure 88 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers

Figure 89 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers

Figure 90 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Others

Figure 91 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others

Figure 92 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease

Figure 93 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease

Figure 94 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease

Figure 95 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease

Figure 96 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease

Figure 97 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease

Figure 98 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia

Figure 99 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia 

Figure 100 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression

Figure 101 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression

Figure 102 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis

Figure 103 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis

Figure 104 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy

Figure 105 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy

Figure 106 : Europe Neurological Biomarkers Market Attractiveness Analysis, By Country

Figure 107 : Europe Neurological Biomarkers Market Attractiveness Analysis, By Type

Figure 108 : Europe Neurological Biomarkers Market Attractiveness Analysis, By Application

Figure 109 : Europe Neurological Biomarkers Market Attractiveness Analysis, By End User

Figure 110 : Asia Pacific Neurological Biomarkers Market Value Share (%) By Type (2017)

Figure 111 : Asia Pacific Neurological Biomarkers Market Value Share (%) By Application (2017)

Figure 112 : Asia Pacific Neurological Biomarkers Market Value Share (%) By End User (2017)

Figure 113 : Asia Pacific Neurological Biomarkers Market Value Share (%) By Country (2017)

Figure 114 : Asia Pacific Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025

Figure 115 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016

Figure 116 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 117 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker

Figure 118 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker

Figure 119 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers

Figure 120 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers

Figure 121 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers

Figure 122 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers

Figure 123 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers

Figure 124 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers

Figure 125 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Others

Figure 126 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others

Figure 127 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease

Figure 128 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease

Figure 129 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease

Figure 130 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease

Figure 131 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease

Figure 132 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease

Figure 133 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia

Figure 134 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia 

Figure 135 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression

Figure 136 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression

Figure 137 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis

Figure 138 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis

Figure 139 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy

Figure 140 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy

Figure 141 : Asia Pacific Neurological Biomarkers Market Attractiveness Analysis, By Country

Figure 142 : Asia Pacific Neurological Biomarkers Market Attractiveness Analysis, By Type

Figure 143 : Asia Pacific Neurological Biomarkers Market Attractiveness Analysis, By Application

Figure 144 : Asia Pacific Neurological Biomarkers Market Attractiveness Analysis, By End User

Figure 145 : Middle East & Africa Neurological Biomarkers Market Value Share (%) By Type (2017)

Figure 146 : Middle East & Africa Neurological Biomarkers Market Value Share (%) By Application (2017)

Figure 147 : Middle East & Africa Neurological Biomarkers Market Value Share (%) By End User (2017)

Figure 148 : Middle East & Africa Neurological Biomarkers Market Value Share (%) By Country (2017)

Figure 149 : Middle East & Africa Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025

Figure 150 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016

Figure 151 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 152 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker

Figure 153 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker

Figure 154 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers

Figure 155 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers

Figure 156 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers

Figure 157 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers

Figure 158 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers

Figure 159 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers

Figure 160 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Others

Figure 161 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others

Figure 162 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease

Figure 163 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease

Figure 164 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease

Figure 165 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease

Figure 166 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease

Figure 167 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease

Figure 168 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia

Figure 169 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia 

Figure 170 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression

Figure 171 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression

Figure 172 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis

Figure 173 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis

Figure 174 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy

Figure 175 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy

Figure 176 : Middle East & Africa Neurological Biomarkers Market Attractiveness Analysis, By Country

Figure 177 : Middle East & Africa Neurological Biomarkers Market Attractiveness Analysis, By Type

Figure 178 : Middle East & Africa Neurological Biomarkers Market Attractiveness Analysis, By Application

Figure 179 : Middle East & Africa Neurological Biomarkers Market Attractiveness Analysis, By End User

Figure 180 : Global Neurology Biomarkers Market Share Analysis (%) By Region, 2017 & 2025

Figure 181 : Global Neurology Biomarkers Market Y-o-Y Growth (%) By Region, 2017–2025

Figure 182 : Global Neurological Biomarkers Market Attractiveness Analysis By Region, 2017–2025

Figure 183 : Global Neurology Biomarkers Market Share Analysis (%) By Type, 2017 & 2025

Figure 184 : Global Neurology Biomarkers Market Y-o-Y Growth (%) By Type, 2017–2025

Figure 185 : Global Neurological Biomarkers Market Attractiveness Analysis By Type, 2017–2025

Figure 186 : Global Neurology Biomarkers Market Share Analysis (%) By Application, 2017 & 2025

Figure 187 : Global Neurology Biomarkers Market Y-o-Y Growth (%) By Application, 2017–2025

Figure 188 : Global Neurological Biomarkers Market Attractiveness Analysis By Application, 2017–2025

Figure 189 : Global Neurology Biomarkers Market Share Analysis (%) By End User, 2017 & 2025

Figure 190 : Global Neurology Biomarkers Market Y-o-Y Growth (%) By End User, 2017–2025

Figure 191 : Global Neurological Biomarkers Market Attractiveness Analysis By End User, 2017–2025

Figure 192 : Global Neurological Biomarkers Market Value Analysis and Forecast, 2016–2025 (US$ Mn)

Figure 193 : Global Neurological Biomarkers Market Absolute $ Opportunity (US$ Mn), 2012–2016

Figure 194 : Global Neurological Biomarkers Market Absolute $ Opportunity (US$ Mn), 2016–2025